Department of Ophthalmology, American University of Beirut, Beirut, Lebanon.
Department of Ophthalmology, Rafic Hariri University Hospital, Beirut, Lebanon.
Br J Ophthalmol. 2018 Oct;102(10):1387-1390. doi: 10.1136/bjophthalmol-2017-311591. Epub 2018 Jan 9.
To assess the two-year outcome of intravitreal ziv-aflibercept (IVZ) in eyes with macular diseases.
Consecutive subjects with various macular diseases that received six or more of 0.05 mL IVZ (1.25 mg) injections with at least 1 year follow-up were included. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution) and central macular thickness (CMT) on spectral domain optical coherence tomography. Paired comparison was done using Wilcoxon signed-rank test calculator.
107 eyes of 91 subjects received IVZ and were followed with mean±SD follow-up interval of 1.48±0.44 months following treat and extend or pro-re-nata protocol. The distribution included neovascular macular degeneration (42 eyes), diabetic macular oedema (32 eyes) and macular oedema secondary to retinal vein occlusion (11 eyes). Fifty eyes were naive, while 57 eyes were previously treated. Combining all disease categories, CMT decreased significantly by 133.0±153.0 µm at the 24-month follow-up (P<0.001) with BCVA gain of 0.35±0.37 at the 24-month follow-up (P<0.001) with mean number of injections of 8.5 at month 12, 2.4 between 12 and 18 month and 1.7 between 18 and 24 month. Ocular and systemic adverse effects included one episode of transient uveitis and one instance of central retinal artery occlusion after 1121 injections.
IVZ appears safe and efficacious in the therapy of macular diseases through 2 years.
评估玻璃体内注射 Ziv-阿柏西普（IVZ）治疗各种黄斑疾病的两年疗效。
纳入了接受了至少 1 年随访且接受了 6 次或以上 0.05ml（1.25mg）IVZ 注射的各种黄斑疾病患者。主要观察指标为最佳矫正视力（BCVA）（最小分辨角对数）和频域光相干断层扫描（OCT）的中心黄斑厚度（CMT）。采用 Wilcoxon 符号秩检验计算器进行配对比较。
91 例患者的 107 只眼接受了 IVZ 治疗，根据延长治疗或按需治疗方案（pro-re-nata），治疗后平均随访间隔为 1.48±0.44 个月。疾病分布包括新生血管性黄斑变性（42 只眼）、糖尿病性黄斑水肿（32 只眼）和视网膜静脉阻塞（11 只眼）所致黄斑水肿。50 只眼为初治，57 只眼为复治。将所有疾病类型合并后，24 个月随访时 CMT 显著下降 133.0±153.0μm（P<0.001），BCVA 提高 0.35±0.37（P<0.001），第 12 个月注射次数为 8.5 次，第 12-18 个月为 2.4 次，第 18-24 个月为 1.7 次。眼部和全身不良反应包括 1 次短暂葡萄膜炎和 1 次视网膜中央动脉阻塞，共发生在 1121 次注射后。
IVZ 治疗黄斑疾病在 2 年内安全有效。
